Investigation of IVS14+1G > A polymorphism of DPYD gene in a group of Turkish patients with colorectal cancer

Anticancer Research

Volumn 27, Issue 6 B, 2007, Pages 3899-3902

  Uzunkoy, Ali ^a   Dilmec, Fuat ^a   Ozgonul, Abdullah ^a   Van Kuilenburg, Andre B P ^b   Akkafa, Feridun ^a  

^a HARRAN UNIVERSITY   (Turkey)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Colorectal cancer; DPYD gene; Polymorphism

Indexed keywords

ADULT; ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; DNA POLYMORPHISM; DPYD GENE; FEMALE; GENE; GENE FREQUENCY; GENE MUTATION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MUTATION RATE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

ALLELES; COLORECTAL NEOPLASMS; DIHYDROURACIL DEHYDROGENASE (NADP); FEMALE; HUMANS; MALE; MIDDLE AGED; MUTATION; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; TURKEY;

EID: 37549027579     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Boyle P and Langman JS: ABC of colorectal cancer. Epidemiology BMJ 321: 805-808, 2000.
2. Gill S, Thomas RR and Goldberg RM: Review article: colorectal cancer chemotherapy. Aliment Pharmacol Ther 18: 683-692, 2003.
3. Goetz MP, Ames MM and Weinshilboum RM: Primer on medical genomics. Part XII: Pharmacogenomics-general principles with cancer as a model. Mayo Clin Proc 79: 376-384, 2004.
4. van Kuilenburg AB, Meinsma R and van Gennip AH: Pyrimidine degradation defects and severe 5-fluorouracil toxicity. Nucleosides Nucleotides Nucleic Acids 23: 1371-1375, 2004.
5. Wei X, Elizondo G, Sapone A, McLeod HL, Raunio H, Fernandez-Salguero P and Gonzalez FJ: Characterization of the human dihydropyrimidine dehydrogenase gene. Genomics 51: 391-400, 1998.
6. van Kuilenburg AB, Vreken P, Abeling NG, Bakker HD, Meinsma R, Van Lenthe H, De Abreu RA, Smeitink JA, Kayserili H, Apak MY, Christensen E, Holopainen I, Pulkki K, Riva D, Botteon G, Holme E, Tulinius M, Kleijer WJ, Beemer FA, Duran M, Niezen-Koning KE, Smit GP, Jakobs C, Smit LM, van Gennip AH et al: Genotype and phenotype in patients with dihydropyrimidine dehydrogenase deficiency. Hum Genet 104: 1-9, 1999.
7. McLeod HL, Collie-Duguid ES, Vreken P, Johnson MR, Wei X, Sapone A, Diasio RB, Fernandez-Salguero P, van Kuilenberg AB, van Gennip AH and Gonzalez FJ: Nomenclature for human DPYD alleles. Pharmacogenetics 8: 455-459, 1998.
8. Ridge SA, Sludden J, Brown O, Robertson L, Wei X, Sapone A, Fernandez-Salguero PM, Gonzalez FJ, Vreken P, van Kuilenburg AB, van Gennip AH and McLeod HL: Dihydropyrimidine dehydrogenase pharmacogenetics in Caucasian subjects. Br J Clin Pharmacol 46: 151-156, 1998.
9. Meinsma R, Fernandez-Salguero P, van Kuilenburg AB, van Gennip AH and Gonzalez FJ: Human polymorphism in drug metabolism: mutation in the dihydropyrimidine dehydrogenase gene results in exon skipping and thymine uracilurea. DNA Cell Biol 14: 1-6, 1995.
10. van Kuilenburg AB: Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. Eur J Cancer 40: 939-950, 2004.
11. Celik I, Kars A, Guc D, Tekuzman G and Ruacan S: Dihydropyrimidine dehydrogenase enzyme deficiency: clinical and genetic assessment of prevalence in Turkish cancer patients. Cancer Invest 20: 333-339, 2002.
12. Magne N, Renee N, Formento JL, Etienne-Grimaldi MC, Francoual M and Milano G: Prospective study of dihydropyrimidine dehydrogenase (DPD) activity and DPYD IVS14+1G > A mutation in patients developing FU-related toxicities: An updated analysis based on a ten-year recruitment across multiple French institutions. J Clin Oncol (Meeting Abstracts) 23: 16S, 2005.
13. Magne N, Etienne-Grimaldi MC, Cals L, Renee N, Formento JL, Francoual M and Milano G: Dihydropyrimidine dehydrogenase activity and the IVS14+1G > A mutation in patients developing 5FU-related toxicity. Br J Clin Pharmacol 64: 237-240, 2007.
14. van Kuilenburg AB, Muller EW, Haasjes J, Meinsma R, Zoetekouw L, Waterham HR, Baas F, Richel DJ and van Gennip AH: Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: frequency of the common IVS14+1G > A mutation causing DPD deficiency. Clin Cancer Res 7: 1149-1153, 2001.
15. Raida M, Schwabe W, Hausler P, van Kuilenburg AB, van Gennip AH, Behnke D and Hoffken K: Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5′-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)-related toxicity compared with controls. Clin Cancer Res 7: 2832-2839, 2001.
16. Salgueiro N, Veiga I, Fragoso M, Sousa O, Costa N, Pellon ML, Sanches E, dos Santos JG, Teixeira MR and Castedo S: Mutations in exon 14 of dihydropyrimidine dehydrogenase and 5-fluorouracil toxicity in Portuguese colorectal cancer patients. Genet Med 6: 102-107, 2004.
17. Suzen HS, Yuce N, Guvenc G, Duydu Y and Erke T: TYMS and DPYD polymorphisms in a Turkish population. Eur J Clin Pharmacol 61: 881-885, 2005.
18. Ciccolini J, Mercier C, Evrard A, Dahan L, Boyer JC, Duffaud F, Richard K, Blanquicett C, Milano G, Blesius A, Durand A, Seitz JF, Favre R and Lacarelle B: A rapid and inexpensive method for anticipating severe toxicity to fluorouracil and fluorouracil-based chemotherapy. Ther Drug Monit 28: 678-685, 2006.
19. Cho HJ, Park YS, Kang WK, Kim JW and Lee SY: Thymidylate synthase (TYMS) and dihydropyrimidine dehydrogenase (DPYD) polymorphisms in the Korean population for prediction of 5-fluorouracil-associated toxicity. Ther Drug Monit 29: 190-196, 2007.
20. Hsiao HH, Yang MY, Chang JG, Liu YC, Liu TC, Chang CS, Chen TP and Lin SF: Dihydropyrimidine dehydrogenase pharmacogenetics in the Taiwanese population. Cancer Chemother Pharmacol 53: 445-451, 2004.
21. Hamdy SI, Hiratsuka M, Narahara K, El-Enany M, Moursi N, Ahmed MS and Mizugaki M: Allele and genotype frequencies of polymorphic cytochromes P450 (CYP2C9, CYP2C19, CYP2E1) and dihydropyrimidine dehydrogenase (DPYD) in the Egyptian population. Br J Clin Pharmacol 53: 596-603, 2002.
22. Ahluwalia R, Freimuth R, McLeod HL and Marsh S: Use of pyrosequencing to detect clinically relevant polymorphisms in dihydropyrimidine dehydrogenase. Clin Chem 49: 1661-1664, 2003.
23. Miller SA, Dykes DD and Polesky HF: A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16: 1215, 1998.
24. van Kuilenburg AB, Haasjes J, Richel DJ, Zoetekouw L, Van Lenthe H, De Abreu RA, Maring JG, Vreken P and van Gennip AH: Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene. Clin Cancer Res 6: 4705-4712, 2000.